Search Result

Results for "

LTB4 antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Calcium Channel (2) CCR (2) Drug Derivative (1) Endogenous Metabolite (3) Interleukin Related (1) Isotope-Labeled Compounds (1) Leukotriene Receptor (35) PGE synthase (1) Platelet-activating Factor Receptor (PAFR) (1) Reference Standards (4) TNF Receptor (1) UGT (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (36)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15744

LY255283 3 Publications Verification	Leukotriene Receptor	Inflammation/Immunology Cancer
LY255283 is a LTB₄ receptor (BLT2) antagonist, with an IC₅₀ of ~100 nM for [ ³H]LTB₄ binding to guinea pig lung membranes .

HY-13628

Etalocib 2 Publications Verification LY293111; VML 295	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111), an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib (LY293111) induces apoptosis .

HY-19304

Amelubant BIIL 284	Leukotriene Receptor	Inflammation/Immunology
Amelubant (BIIL 284) is a potent, oral and long acting LTB₄ receptor antagonist, negligibly binds to LTB₄ receptor, with K_is of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .

HY-103360

J-113863 3 Publications Verification	CCR	Inflammation/Immunology
J-113863 is a potent and selective CCR1 antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .

HY-114641A

BIIL-260 hydrochloride 1 Publications Verification	Leukotriene Receptor	Inflammation/Immunology
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor *LTB₄* antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with K_i values of 1.7 nM .

HY-108396

γ-Linolenic acid ethyl ester Ethyl γ-linolenate	Leukotriene Receptor	Inflammation/Immunology
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist .

HY-149084

LTB4 antagonist 3	Leukotriene Receptor	Inflammation/Immunology
LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist with an IC₅₀ value of 477 nM. LTB4 antagonist 3 has anti-inflammatory activity .

HY-112742

CP-195543	Leukotriene Receptor	Inflammation/Immunology
CP-195543 is a potent, selective and orally active *leukotriene B4 (LTB4) receptor* antagonist with IC₅₀s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .

HY-149083

LTB4 antagonist 2	Leukotriene Receptor	Inflammation/Immunology
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC₅₀ of 439 nM .

HY-149082

LTB4 antagonist 1	Leukotriene Receptor	Inflammation/Immunology
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC₅₀ of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties .

HY-N4267

Yangambin	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits *LTB₄*-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-124100

LTB4 antagonist 4	Drug Derivative	Others
LTB4 antagonist 4 is an active compound.

HY-112741

SB-209247 1 Publications Verification	Leukotriene Receptor	Inflammation/Immunology
SB-209247 is a selective, high affinity and orally active *leukotriene B4 (LTB4) receptor* antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca ²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .

HY-155300

BLT2 antagonist-1	Leukotriene Receptor	Inflammation/Immunology
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC₅₀ of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a K_i value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .

HY-100173

DW-1350	Leukotriene Receptor	Inflammation/Immunology
DW-1350 is a LTB₄ receptor antagonist.

HY-112740

SC-53228	Leukotriene Receptor	Inflammation/Immunology
SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis .

HY-117896

SC-50605	Leukotriene Receptor	Inflammation/Immunology
SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .

HY-123014

(Rac)-SC-45694	Leukotriene Receptor	Cancer
(Rac)-SC-45694 is a racemate of SC-45694. SC-45694 has full *LTB4* agonist activity for neutrophil chemotaxis and has antagonist activity against LTB4-induced neutrophil degranulation .

HY-139112

Leukotriene B4 dimethyl amide	Leukotriene Receptor	Inflammation/Immunology
Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology .

HY-114641

BIIL-260	Leukotriene Receptor	Inflammation/Immunology
BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor *LTB₄* antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with the K_i value of 1.7 nM .

HY-122536

Ricinelaidic acid	Leukotriene Receptor Calcium Channel Endogenous Metabolite	Inflammation/Immunology
Ricinelaidic acid, a 12-hydroxy fatty acid，is a *leukotriene B4 (LTB4) receptor* antagonist with the K_i of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC₅₀=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .

HY-13628A

Etalocib sodium LY293111 sodium; VML 295 sodium	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111) sodium, an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib sodium prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib sodium induces apoptosis .

HY-131651

Leukotriene B4 ethanolamide LTB4 ethanolamide	Endogenous Metabolite Leukotriene Receptor	Cancer
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .

HY-U00263

LY210073	Leukotriene Receptor	Inflammation/Immunology
LY210073 is a Leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 6.2 nM.

HY-106929B

Moxilubant hydrochloride CGS 25019C hydrochloride	Leukotriene Receptor	Inflammation/Immunology
Moxilubant (CGS 25019C) hydrochloride is an orally active BLT1 antagonist. Moxilubant hydrochloride inhibits *LTB4* signaling with a potency of 2-4 nM. Moxilubant hydrochloride blocks LTB4-induced neutrophil functions. Moxilubant hydrochloride inhibits ear edema and neutrophil infiltration in mice. Moxilubant hydrochloride can be used in research related to chronic obstructive pulmonary disease .

HY-106929

Moxilubant 1 Publications Verification CGS 25019C free base	Leukotriene Receptor	Inflammation/Immunology
Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits *LTB4* signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease .

HY-13628R

Etalocib (Standard) LY293111 (Standard); VML 295 (Standard)	Leukotriene Receptor Apoptosis Reference Standards	Inflammation/Immunology Cancer
Etalocib (Standard) is the analytical standard of Etalocib. This product is intended for research and analytical applications. Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .

HY-117557

LY306669	Leukotriene Receptor	Inflammation/Immunology
LY306669 is a potent and selective leukotriene B4 (LTB4) receptor antagonist that can be used for the research of lung injury .

HY-115390

14,15-Dehydro Leukotriene B4	Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a K_i value of 27 nM and BLT2 with a K_i value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC₅₀ value of 1 µM .

HY-19198

SB-201993	Leukotriene Receptor	Inflammation/Immunology
SB-201993 is a selective leukotriene B₄ (LTB4) receptor antagonist with a K_i=7.6 nM for LTB4 receptors on human inflammatory cells. SB-201993 inhibits calcium mobilization in inflammatory cells and 5-lipoxygenase activity, exerting anti-inflammatory effects. SB-201993 is promising for research of inflammatory diseases (e.g., dermatitis, arthritis) .

HY-117706

LY 292728	Leukotriene Receptor	Inflammation/Immunology
LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a K_i of 0.47 nM and binds to guinea pig lung membranes with a K_i of 0.04 nM .

HY-117854

SB 201146	Leukotriene Receptor	Inflammation/Immunology
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .

HY-W744842

γ-Linolenic acid ethyl ester-d5 Ethyl γ-linolenate-d₅	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology
γ-Linolenic acid ethyl ester-d₅ (Ethyl γ-linolenate-d₅) is the deuterium labeled γ-Linolenic acid ethyl ester (HY-108396). γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .

HY-123014A

SC-45694 lithium	Leukotriene Receptor	Inflammation/Immunology
SC-45694 (lithium) is an analog of LTB₄. SC-45694 (lithium) exhibits an agonist activity against *LTB₄* for chemotaxis and an antagonist activity against LTB₄-induced degranulation. SC-45694 (lithium) stimulates neutrophil chemotaxis .

HY-121621

RO5101576	Endogenous Metabolite	Inflammation/Immunology
RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .

HY-106929R

Moxilubant (Standard) CGS 25019C free base (Standard)	Leukotriene Receptor Reference Standards	Inflammation/Immunology
Moxilubant (CGS 25019C free base) Standard is the analytical standard of Moxilubant (HY-106929). This product is intended for research and analytical applications. Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits *LTB4* signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease .

HY-180411

SM-15178	Leukotriene Receptor	Inflammation/Immunology
SM-15178 is a potent, orally active and selective leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 0.30 μM. SM-15178 attenuates *LTB*₄ (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma .

HY-108396R

γ-Linolenic acid ethyl ester (Standard) Ethyl γ-linolenate (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology
γ-Linolenic acid ethyl ester (Standard) is the analytical standard of γ-Linolenic acid ethyl ester (HY-108396). This product is intended for research and analytical applications. γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .

HY-103360R

J-113863 (Standard)	Reference Standards CCR	Inflammation/Immunology
J-113863 (Standard) is the analytical standard of J-113863 (HY-103360). This product is intended for research and analytical applications. J-113863 is a potent and selective CCR1 antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits *LTB₄*-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

Cat. No.	Product Name	Chemical Structure

HY-W744842

γ-Linolenic acid ethyl ester-d5
γ-Linolenic acid ethyl ester-d₅ (Ethyl γ-linolenate-d₅) is the deuterium labeled γ-Linolenic acid ethyl ester (HY-108396). γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LTB4 antagonist

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products